周三盘中，中国生物制药（01177.HK）股价出现显著下跌，截至下午1时01分，该股大跌5.11%，报3.53港元。尽管盘中出现大幅下跌，但市场上仍有大手交易活跃，同时券商对该公司前景保持乐观态度。
盘中交易数据显示，中国生物制药早盘出现多笔大手交易。上午10时35分左右，有93.1万股以3.59港元的价格被大手卖出，涉资约334.23万港元。而在此之前的10时09分，市场上还出现了110万股的大手买入，成交价为3.6港元，涉资396万港元。这些大额交易反映出机构投资者对该股态度出现分歧。
值得注意的是，尽管股价出现大幅下跌，但大和证券最新发布的研报对中国生物制药保持看好态度。大和证券将公司目标价从3.5港元上调至4港元，并重申"买入"评级。研报指出，中国生物制药去年业绩表现良好，收入同比增长10.2%，主要受创新药带动；毛利率同比上升0.5个百分点；经调整净利润增长33.5%。大和证券还上调了公司未来两年的创新药收入预测，显示出对公司发展前景的信心。然而，尽管有利好分析，市场短期内仍呈现出谨慎态度，导致股价出现较大幅度的调整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.